At a glance
- Originator Sanofi-Synthelabo
- Class Antiarrhythmics; Benzamides; Ischaemic heart disorder therapies; Vasodilators
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 22 Nov 1995 Suspended - Preclinical for Angina pectoris in France (Unknown route)
- 22 Nov 1995 Suspended - Preclinical for Angina pectoris in USA (Unknown route)
- 11 Oct 1995 Preclinical development for Arrhythmias in France (Unknown route)